Back to top
more

Arbutus Biopharma (ABUS)

(Delayed Data from NSDQ)

$2.73 USD

2.73
406,742

+0.01 (0.37%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $2.72 -0.01 (-0.37%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Arbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Arbutus (ABUS) delivered earnings and revenue surprises of 0% and 54.70%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Arbutus (ABUS) to Focus on Hepatitis B Candidates, Stock Up

by Zacks Equity Research

Arbutus (ABUS) makes a strategic decision to focus on the development of hepatitis B virus therapies while discontinuing all coronavirus and oral RNA destabilizer programs.

Arbutus Biopharma (ABUS) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Arbutus (ABUS) delivered earnings and revenue surprises of 16.67% and 7.39%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Are Medical Stocks Lagging Amphastar Pharmaceuticals (AMPH) This Year?

by Zacks Equity Research

Here is how Amphastar Pharmaceuticals (AMPH) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.

Is Amphastar Pharmaceuticals (AMPH) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Amphastar Pharmaceuticals (AMPH) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.

Biohaven (BHVN) Stock up 8% on Encouraging Pipeline Updates

by Zacks Equity Research

At its R&D Day, Biohaven (BHVN) provides updates on its pipeline. It also announced submission of a regulatory filing seeking approval for troriluzole in SCA3, an ultra-rare disorder.

Valneva (VALN) Stock Down 53% in the Past Year: Here's Why

by Zacks Equity Research

The European Commission's revised advance purchase agreement jeopardizes Valneva's (VALN) COVID-19 vaccine program.

FDA Accepts Iovance's (IOVA) BLA Filing for Melanoma Drug

by Zacks Equity Research

The FDA grants priority review to Iovance's (IOVA) filing seeking approval for its lead pipeline candidate in melanoma indication. A decision is expected before November-end.

Is Amphastar Pharmaceuticals (AMPH) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Amphastar Pharmaceuticals (AMPH) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.

Arbutus (ABUS) Upgraded to Buy: Here's Why

by Zacks Equity Research

Arbutus (ABUS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Arbutus Biopharma (ABUS) and Hologic (HOLX) have performed compared to their sector so far this year.

Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Arbutus (ABUS) delivered earnings and revenue surprises of 28.57% and 47.94%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 33.56% and 13.60%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Arbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Arbutus (ABUS) delivered earnings and revenue surprises of 0% and 1.03%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

ADC Therapeutics SA (ADCT) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 38.78% and 7.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -5.26% and 37.83%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Vericel Corporation (VCEL) Surges 16.3%: Is This an Indication of Further Gains?

by Zacks Equity Research

Vericel Corporation (VCEL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Arbutus (ABUS) delivered earnings and revenue surprises of 0% and 46.45%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Albireo Pharma (ALBO) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Albireo Pharma (ALBO) delivered earnings and revenue surprises of -1.61% and 1.58%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Arbutus Biopharma (ABUS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Arbutus (ABUS) delivered earnings and revenue surprises of 23.08% and 165.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Bristol Myers Squibb (BMY) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Bristol Myers (BMY) delivered earnings and revenue surprises of 7.82% and 3.72%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

All You Need to Know About Arbutus (ABUS) Rating Upgrade to Buy

by Zacks Equity Research

Arbutus (ABUS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Arbutus (ABUS) delivered earnings and revenue surprises of 15.38% and 118.16%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -50.57% and 87.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Arbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Arbutus (ABUS) delivered earnings and revenue surprises of 6.25% and 5.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?